China Universal Asset Management Co. Ltd. Purchases 909 Shares of United Therapeutics Co. (NASDAQ:UTHR)

China Universal Asset Management Co. Ltd. lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 9,466 shares of the biotechnology company’s stock after buying an additional 909 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $3,340,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. Caprock Group LLC grew its holdings in United Therapeutics by 16.3% during the 4th quarter. Caprock Group LLC now owns 792 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 111 shares during the last quarter. Mediolanum International Funds Ltd lifted its holdings in shares of United Therapeutics by 8.7% during the fourth quarter. Mediolanum International Funds Ltd now owns 5,221 shares of the biotechnology company’s stock worth $1,863,000 after purchasing an additional 417 shares during the period. EMC Capital Management grew its stake in shares of United Therapeutics by 9.5% in the fourth quarter. EMC Capital Management now owns 1,577 shares of the biotechnology company’s stock worth $556,000 after purchasing an additional 137 shares during the last quarter. Capital Investment Advisory Services LLC increased its holdings in United Therapeutics by 12.9% in the fourth quarter. Capital Investment Advisory Services LLC now owns 1,242 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 142 shares during the period. Finally, Milestone Asset Management LLC raised its position in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 1,037 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 133,838 shares of company stock worth $50,445,556 in the last ninety days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $351.17 on Friday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The stock has a market capitalization of $15.68 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The company’s 50-day moving average is $365.03 and its 200-day moving average is $356.94.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter last year, the firm posted $5.38 earnings per share. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on UTHR shares. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.